GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Cyclically Adjusted PS Ratio

Azenta (Azenta) Cyclically Adjusted PS Ratio : 5.98 (As of Jun. 06, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Azenta Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Azenta's current share price is $52.99. Azenta's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $8.86. Azenta's Cyclically Adjusted PS Ratio for today is 5.98.

The historical rank and industry rank for Azenta's Cyclically Adjusted PS Ratio or its related term are showing as below:

AZTA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.9   Med: 3.71   Max: 15.86
Current: 5.93

During the past years, Azenta's highest Cyclically Adjusted PS Ratio was 15.86. The lowest was 0.90. And the median was 3.71.

AZTA's Cyclically Adjusted PS Ratio is ranked worse than
75.05% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 2.15 vs AZTA: 5.93

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Azenta's adjusted revenue per share data for the three months ended in Mar. 2024 was $2.870. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $8.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Azenta Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Azenta's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Cyclically Adjusted PS Ratio Chart

Azenta Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.42 5.84 13.21 5.24 5.80

Azenta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.33 5.49 5.80 7.52 6.80

Competitive Comparison of Azenta's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Azenta's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Azenta's Cyclically Adjusted PS Ratio falls into.



Azenta Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Azenta's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=52.99/8.86
=5.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Azenta's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Azenta's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.87/131.7762*131.7762
=2.870

Current CPI (Mar. 2024) = 131.7762.

Azenta Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.735 100.560 2.274
201409 1.802 100.428 2.364
201412 1.828 99.070 2.431
201503 2.036 99.621 2.693
201506 2.113 100.684 2.766
201509 2.124 100.392 2.788
201512 1.761 99.792 2.325
201603 1.973 100.470 2.588
201606 2.133 101.688 2.764
201609 0.455 101.861 0.589
201612 2.289 101.863 2.961
201703 2.414 102.862 3.093
201706 2.581 103.349 3.291
201709 0.231 104.136 0.292
201712 2.012 104.011 2.549
201803 2.223 105.290 2.782
201806 2.428 106.317 3.009
201809 2.250 106.507 2.784
201812 2.486 105.998 3.091
201903 2.744 107.251 3.371
201906 2.813 108.070 3.430
201909 -3.408 108.329 -4.146
201912 2.858 108.420 3.474
202003 2.985 108.902 3.612
202006 2.983 108.767 3.614
202009 -3.543 109.815 -4.252
202012 1.590 109.897 1.907
202103 1.744 111.754 2.056
202106 1.737 114.631 1.997
202109 1.820 115.734 2.072
202112 1.865 117.630 2.089
202203 1.942 121.301 2.110
202206 1.770 125.017 1.866
202209 1.835 125.227 1.931
202212 2.459 125.222 2.588
202303 2.147 127.348 2.222
202306 2.616 128.729 2.678
202309 2.895 129.860 2.938
202312 2.721 129.419 2.771
202403 2.870 131.776 2.870

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Azenta  (NAS:AZTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Azenta Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Azenta's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta (Azenta) Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha officer: SVP, GM BLS-Products 15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824